6533b85bfe1ef96bd12bb3e6
RESEARCH PRODUCT
false
subject
0301 basic medicinemedicine.medical_specialtyLipopolysaccharideBiologyCoagulation Factor IXmedicine.diseaseIntestinal epitheliumInflammatory bowel diseaseGeneral Biochemistry Genetics and Molecular BiologyCXCL103 medical and health scienceschemistry.chemical_compound030104 developmental biology0302 clinical medicineEndocrinologychemistryInternal medicinemedicine030211 gastroenterology & hepatologyColitisGeneral Agricultural and Biological SciencesReceptorAcute colitisdescription
Patients with inflammatory bowel disease (IBD) are susceptible to thromboembolism. Interestingly, IBD occurs less frequently in patients with inherited bleeding disorders. Therefore, we analyzed whether F9-deficiency is protective against the onset of acute colitis in a genetic hemophilia B mouse model. In the 3.5% dextran sulfate sodium (DSS)-induced colitis model, F9-deficient mice were protected from body-weight loss and had a reduced disease activity score. We detected decreased colonic myeloperoxidase activity and decreased CXCL1 levels in DSS-treated F9-deficient mice compared with wild-type (WT) littermate controls, indicating decreased neutrophil infiltration. Remarkably, we identified expression of coagulation factor IX (FIX) protein in small intestinal epithelial cells (MODE-K). In epithelial cell cultures, cellular FIX protein expression was increased following stimulation with the bacterial Toll-like receptor agonists lipopolysaccharide, macrophage-activating lipopeptide-2 and Pam3CSK4. Thus, we revealed a protective role of F9-deficiency in DSS-induced colitis and identified the intestinal epithelium as a site of ectopic FIX.This article has an associated First Person interview with the first author of the paper.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2018-01-01 | Biology Open |